Literature DB >> 7654479

Urinary recovery and kinetics of sulphamethoxazole and its metabolites in HIV-seropositive patients and healthy volunteers after a single oral dose of sulphamethoxazole.

A J van der Ven1, T B Vree, E W van Ewijk-Beneken Kolmer, P P Koopmans, J W van der Meer.   

Abstract

1. The urinary excretion of sulphamethoxazole and its metabolites was compared between healthy volunteers and HIV-seropositive patients in order to get a better understanding of why HIV seropositives are more predisposed to idiosyncratic toxicity of sulphonamides. 2. A single 800 mg oral dose of sulphamethoxazole was administered to seven healthy volunteers and seven asymptomatic HIV seropositives without previous use of sulphonamides. 3. Urine was collected for 4 days and drug analysis was by h.p.l.c. 4. No difference was observed between seropositive and seronegative individuals in the urinary recovery of sulphamethoxazole, N4-acetyl-, 5-hydroxy-, N4-acetyl-5-hydroxy-sulphamethoxazole and the N1-glucuronide conjugate. However the recovery of the hydroxylamine metabolite of sulphamethoxazole was significantly lower in the HIV seropositives (0.50 +/- 0.51 vs 2.23 +/- 0.85%; 95% CI on the difference, -0.90 to -2.55; P = 0.0006). 5. Sulphamethoxazole hydroxylamine may be a factor in the susceptibility of HIV infected individuals to sulphonamides.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7654479      PMCID: PMC1365073          DOI: 10.1111/j.1365-2125.1995.tb05721.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  Serum trimethoprim and sulphamethoxazole levels in AIDS.

Authors:  F J Bowden; P J Harman; C R Lucas
Journal:  Lancet       Date:  1986-04-12       Impact factor: 79.321

2.  Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides.

Authors:  M J Rieder; J Uetrecht; N H Shear; S P Spielberg
Journal:  J Pharmacol Exp Ther       Date:  1988-02       Impact factor: 4.030

3.  Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study.

Authors:  F R Sattler; R Cowan; D M Nielsen; J Ruskin
Journal:  Ann Intern Med       Date:  1988-08-15       Impact factor: 25.391

4.  Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial.

Authors:  J M Wharton; D L Coleman; C B Wofsy; J M Luce; W Blumenfeld; W K Hadley; L Ingram-Drake; P A Volberding; P C Hopewell
Journal:  Ann Intern Med       Date:  1986-07       Impact factor: 25.391

5.  Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies.

Authors:  J A Kovacs; J W Hiemenz; A M Macher; D Stover; H W Murray; J Shelhamer; H C Lane; C Urmacher; C Honig; D L Longo
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

6.  Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome.

Authors:  F M Gordin; G L Simon; C B Wofsy; J Mills
Journal:  Ann Intern Med       Date:  1984-04       Impact factor: 25.391

7.  The treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.

Authors:  C B Small; C A Harris; G H Friedland; R S Klein
Journal:  Arch Intern Med       Date:  1985-05

8.  Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men.

Authors:  H S Jaffe; D I Abrams; A J Ammann; B J Lewis; J A Golden
Journal:  Lancet       Date:  1983-11-12       Impact factor: 79.321

9.  Isolation, identification and determination of sulfamethoxazole and its known metabolites in human plasma and urine by high-performance liquid chromatography.

Authors:  T B Vree; A J van der Ven; C P Verwey-van Wissen; E W van Ewijk-Beneken Kolmer; A E Swolfs; P M van Galen; H Amatdjais-Groenen
Journal:  J Chromatogr B Biomed Appl       Date:  1994-08-19

10.  In vitro evaluation of a toxic metabolite of sulfadiazine.

Authors:  N H Shear; S P Spielberg
Journal:  Can J Physiol Pharmacol       Date:  1985-11       Impact factor: 2.273

View more
  6 in total

1.  Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo.

Authors:  D J Naisbitt; S F Gordon; M Pirmohamed; C Burkhart; A E Cribb; W J Pichler; B K Park
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Fate of 14C-acetyl sulfamethoxazole during the activated sludge process.

Authors:  Chunnu Geng; Yujia Zhuang; Valérie Bergheaud; Patricia Garnier; Claire-Sophie Haudin
Journal:  Environ Sci Pollut Res Int       Date:  2019-02-08       Impact factor: 4.223

3.  Bioactivation, protein haptenation, and toxicity of sulfamethoxazole and dapsone in normal human dermal fibroblasts.

Authors:  Payal Bhaiya; Sanjoy Roychowdhury; Piyush M Vyas; Mark A Doll; David W Hein; Craig K Svensson
Journal:  Toxicol Appl Pharmacol       Date:  2006-04-17       Impact factor: 4.219

Review 4.  Role of viral infections in the induction of adverse drug reactions.

Authors:  M Levy
Journal:  Drug Saf       Date:  1997-01       Impact factor: 5.228

5.  Rifampin reduces concentrations of trimethoprim and sulfamethoxazole in serum in human immunodeficiency virus-infected patients.

Authors:  E Ribera; L Pou; A Fernandez-Sola; F Campos; R M Lopez; I Ocaña; I Ruiz; A Pahissa
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

6.  Hepatic expression profiles in retroviral infection: relevance to drug hypersensitivity risk.

Authors:  Yat Yee Wong; Brian Johnson; Thomas C Friedrich; Lauren A Trepanier
Journal:  Pharmacol Res Perspect       Date:  2017-04-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.